1 0

    FDA Orange Book Exclusivity Evaluation for NDA 217779 – RYTELO (Imetelstat Sodium)

    FDA Orange Book Exclusivity Evaluation for NDA 217779 – RYTELO (Imetelstat Sodium)

    $69.00 USD
    $69.00 USD
    Sale Sold out
    Original Request: Please provide a copy of the Orange Book’s Exclusivity Eligibility Evaluation for NDA 217779 for RYTELO (imetelstat sodium), approved on June 6, 2024. Please provide the responsive items electronically by email if possible.
    Tags: Pharma, NDA, 2024

    NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.

    View full details